Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) Sees Large Decline in Short Interest

Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) saw a significant decrease in short interest during the month of September. As of September 15th, there was short interest totaling 13,144 shares, a decrease of 52.5% from the August 31st total of 27,645 shares. Based on an average daily trading volume, of 422,623 shares, the days-to-cover ratio is presently 0.0 days. Currently, 0.0% of the company’s shares are sold short.

Oncotelic Therapeutics Trading Down 9.6%

OTLC traded down $0.00 during mid-day trading on Tuesday, hitting $0.02. 428,267 shares of the stock were exchanged, compared to its average volume of 283,978. The firm’s fifty day moving average is $0.03 and its two-hundred day moving average is $0.04. Oncotelic Therapeutics has a 1-year low of $0.01 and a 1-year high of $0.11. The company has a market cap of $10.73 million, a PE ratio of 0.04 and a beta of -0.24. The company has a current ratio of 0.08, a quick ratio of 0.08 and a debt-to-equity ratio of 0.01.

About Oncotelic Therapeutics

Oncotelic Therapeutics, Inc is a clinical-stage biotechnology company focused on developing novel therapies for cancer and other serious diseases. The company’s research platform emphasizes RNA-based therapeutics and targets biological pathways involved in tumor growth, immune response, and disease progression.

Its principal investigational product is OT-101, also known as trabedersen, an antisense oligonucleotide designed to inhibit transforming growth factor beta 2 (TGF-β2). Oncotelic has studied OT-101 in several oncology settings, including brain and other solid tumors.